LMR Partners’s Aligos Therapeutics ALGS Stock Holding History

LMR Partners’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,000	Closed	-$17.5K	–	1259
2024 Q2	$17.5K	Buy	+2,000	New	+$35.2K	﹤0.01%	987

Other funds holding ALGS

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LMR Partners's ALGS Position: Q3 2024 in Review

LMR Partners sold out of Aligos Therapeutics (ALGS) in Q3 2024, closing a stake of 2,000 shares — an estimated $17.5K sold.

LMR Partners first reported a position in ALGS in Q2 2024 and held it in 1 quarter. The position peaked at $17.5K in Q2 2024. 27 funds tracked by Wall St. Rank hold ALGS as of Q3 2024.

LMR Partners reported no remaining Aligos Therapeutics position as of Q3 2024 after selling out during the quarter.
LMR Partners sold 2,000 Aligos Therapeutics shares in Q3 2024, an estimated $17.5K.
LMR Partners first reported a position in Aligos Therapeutics in Q2 2024 and held it in 1 quarter.
LMR Partners's Aligos Therapeutics position peaked at $17.5K in Q2 2024.
27 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2024.

Based on LMR Partners's 13F filing for Q3 2024, filed 7 Nov 2024.